Drug interactions
Encorafenib + Paclitaxel
Severity: Moderate
Encorafenib and Paclitaxel: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Encorafenib can both inhibit and induce CYP3A4 and may inhibit OATP1B1/1B3 transporters, so paclitaxel exposure may change unpredictably. Increased toxicity or reduced efficacy is possible.
What this interaction means in plain words
Encorafenib and Paclitaxel can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Encorafenib belongs to Oncology; Paclitaxel belongs to Oncology.
Why it happens
Mixed CYP3A4 inhibition and induction plus OATP inhibition by encorafenib alter paclitaxel disposition.
What to do
Monitor for paclitaxel toxicity such as neutropenia and neuropathy, and for loss of efficacy. Adjust the paclitaxel dose according to tolerance.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Encorafenib and Paclitaxel, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Paclitaxel
Other interactions of Encorafenib
Frequently asked questions
Can I take Encorafenib with Paclitaxel?
MediHelp rates the interaction as moderate. Encorafenib and Paclitaxel can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Encorafenib can both inhibit and induce CYP3A4 and may inhibit OATP1B1/1B3 transporters, so paclitaxel exposure may change unpredictably. Increased toxicity or reduced efficacy is possible.
How serious is the interaction between Encorafenib and Paclitaxel?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for paclitaxel toxicity such as neutropenia and neuropathy, and for loss of efficacy. Adjust the paclitaxel dose according to tolerance.
What other medicines interact with Paclitaxel?
MediHelp also lists interactions of Paclitaxel with, for example, Adenovirus types 4 and 7 live, Cobicistat, Cyclosporine. The full list is on the Paclitaxel page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
